Detalles de la búsqueda
1.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med;
389(4): 335-347, 2023 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272512
2.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood;
143(20): 2029-2036, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394666
3.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Blood;
143(13): 1242-1258, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096363
4.
Quad-class exposed/refractory myeloma is associated with short survival.
Br J Haematol;
204(1): 186-190, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37833834
5.
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03.
Br J Haematol;
2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38811169
6.
T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Blood;
139(26): 3681-3687, 2022 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35404996
7.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood;
139(4): 492-501, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34269818
8.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood;
139(18): 2747-2757, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35511184
9.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Eur J Haematol;
2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38712850
10.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Am J Hematol;
99(3): 350-359, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38165016
11.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol;
24(6): e255-e269, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269857
12.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood;
138(2): 113-121, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827114
13.
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Blood;
138(25): 2686-2695, 2021 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34479366
14.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica;
108(10): 2774-2782, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37078253
15.
Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.
Eur Radiol;
33(9): 6438-6447, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022439
16.
Clinical features and outcomes of patients admitted to the ICU for Cyclophosphamide-associated cardiac toxicity: a retrospective cohort.
Support Care Cancer;
31(8): 474, 2023 Jul 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37462731
17.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Br J Haematol;
198(6): 988-993, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608261
18.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol;
196(3): 639-648, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34671975
19.
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Br J Haematol;
197(1): 82-96, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35166376
20.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood;
135(18): 1531-1540, 2020 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32108228